Illumina, Inc. $ILMN Shares Sold by Weil Company Inc.

Weil Company Inc. trimmed its position in Illumina, Inc. (NASDAQ:ILMN) by 17.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 14,600 shares of the life sciences company’s stock after selling 3,103 shares during the quarter. Weil Company Inc.’s holdings in Illumina were worth $3,996,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in ILMN. Fiduciary Financial Advisors purchased a new position in shares of Illumina during the second quarter valued at $26,000. MCF Advisors LLC lifted its stake in Illumina by 172.4% in the second quarter. MCF Advisors LLC now owns 158 shares of the life sciences company’s stock worth $28,000 after acquiring an additional 100 shares during the period. Keating Financial Advisory Services Inc. purchased a new stake in Illumina in the second quarter worth about $32,000. Rakuten Securities Inc. purchased a new stake in Illumina in the second quarter worth about $33,000. Finally, Elevation Wealth Partners LLC grew its holdings in Illumina by 52.5% during the 2nd quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock worth $43,000 after acquiring an additional 84 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina News Roundup

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: BioInsight Platform strengthens Illumina’s AI and software narrative. The company launched a unified environment combining genomic and multiomic analysis tools, purpose-built AI, curated biological data, and an updated DRAGEN secondary-analysis offering. The platform could make Illumina’s tools easier to use, support recurring software revenue, and help researchers move faster from sequencing data to actionable insights. Illumina BioInsight Platform announcement
• Positive Sentiment: SpliceAI2 may broaden the clinical-genomics opportunity. Coverage of Illumina’s new genomic model suggests that advances in AI-driven variant interpretation could improve the company’s positioning in clinical testing and precision medicine, though commercial adoption and regulatory validation remain key uncertainties. SpliceAI2 coverage
• Neutral Sentiment: Illumina established a $1 billion commercial-paper program and a new dealer agreement. The arrangements should improve short-term financing flexibility, but they also provide access to additional borrowing and are not, by themselves, evidence of higher operating performance. Commercial paper program announcement
• Neutral Sentiment: Upcoming third-quarter results are expected to show only low-single-digit earnings growth. The earnings preview gives investors a near-term catalyst, but expectations appear modest compared with the stock’s substantial recent rally. Illumina earnings preview
• Negative Sentiment: Valuation has become a significant concern. Analysts note that ILMN’s large share-price gain may already reflect much of the expected sequencing recovery and AI upside, leaving less room for disappointment if growth or cash-flow improvement slows. Illumina valuation analysis
• Negative Sentiment: A voluntary global recall affects certain diagnostic sequencers because of a DRAGEN server security vulnerability. The issue reportedly involves server configuration rather than sequencing accuracy or core hardware, and 80 units are affected. Even so, remediation costs, customer disruption, and cybersecurity concerns could weigh on sentiment. Illumina diagnostic sequencer recall

Illumina Trading Up 0.2%

ILMN opened at $271.76 on Thursday. The firm has a market cap of $41.04 billion, a price-to-earnings ratio of 50.70, a PEG ratio of 3.84 and a beta of 1.41. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. Illumina, Inc. has a 12 month low of $90.10 and a 12 month high of $309.35. The stock has a fifty day moving average price of $231.55 and a 200-day moving average price of $184.42.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%. The firm had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. During the same period in the prior year, the business posted $1.19 EPS. The firm’s quarterly revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities research analysts anticipate that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Illumina news, Director Keith Meister sold 457,858 shares of the business’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total value of $91,617,385.80. Following the completion of the transaction, the director directly owned 2,372,694 shares in the company, valued at approximately $474,776,069.40. The trade was a 16.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have sold 2,061,850 shares of company stock valued at $436,479,102 in the last ninety days. Insiders own 2.90% of the company’s stock.

Analysts Set New Price Targets

ILMN has been the topic of a number of research reports. Leerink Partners raised their target price on shares of Illumina from $220.00 to $300.00 and gave the company an “outperform” rating in a research report on Tuesday, September 29th. JPMorgan Chase & Co. boosted their price target on shares of Illumina from $220.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Citigroup upped their price target on shares of Illumina from $95.00 to $113.00 and gave the stock a “sell” rating in a research report on Monday, August 3rd. Zacks Research downgraded shares of Illumina from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 1st. Finally, Sanford C. Bernstein reiterated a “market perform” rating and set a $215.00 price objective on shares of Illumina in a research note on Friday, July 31st. Ten analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Illumina currently has a consensus rating of “Hold” and an average price target of $225.94.

About Illumina

Illumina, Inc develops and manufactures technologies used to analyze genetic variation and biological function. Its products are primarily based on next-generation sequencing, a method that enables researchers and clinicians to read DNA and RNA for applications including genomic research, disease studies, drug development and clinical testing.

The company offers sequencing instruments, consumables such as reagent kits and flow cells, and related software and informatics solutions. Illumina also provides services and support designed to help customers prepare samples, run sequencing workflows, interpret genomic data and integrate results into research or clinical operations.

Founded in 1998 and headquartered in San Diego, California, Illumina serves customers worldwide, including academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, clinical laboratories and other healthcare organizations.